In spite of Lucira Health Inc.’s (NASDAQ:LHDX) recent upswing, most analysts remain bearish.

In the latest session, Lucira Health Inc. (NASDAQ: LHDX) closed at $0.48 up 15.72% from its previous closing price of $0.41. In other words, the price has increased by $+0.0652 from its previous closing price. On the day, 839261 shares were traded.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Ratios:

For a deeper understanding of Lucira Health Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.16.

Upgrades & Downgrades

On April 13, 2021, BofA Securities Downgraded its rating to Underperform which previously was Neutral but kept the price unchanged to $9.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 16 when Kashmolah Ghazi sold 4,790 shares for $0.35 per share. The transaction valued at 1,676 led to the insider holds 179,887 shares of the business.

Allen Anthony Joseph sold 17,052 shares of LHDX for $23,702 on Sep 20. The Chief Operations Officer now owns 183,617 shares after completing the transaction at $1.39 per share. On Sep 18, another insider, George Dan, who serves as the CFO and Treasurer of the company, sold 343 shares for $1.38 each. As a result, the insider received 473 and left with 46,011 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.10 while its Price-to-Book (P/B) ratio in mrq is 0.10.

Stock Price History:

Over the past 52 weeks, LHDX has reached a high of $9.63, while it has fallen to a 52-week low of $0.32. The 50-Day Moving Average of the stock is 1.0412, while the 200-Day Moving Average is calculated to be 2.4248.

Shares Statistics:

For the past three months, LHDX has traded an average of 94.56K shares per day and 379.02k over the past ten days. A total of 39.93M shares are outstanding, with a floating share count of 36.58M. Insiders hold about 3.40% of the company’s shares, while institutions hold 57.30% stake in the company. Shares short for LHDX as of Oct 13, 2022 were 71.41k with a Short Ratio of 0.07M, compared to 84.41k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.18% and a Short% of Float of 0.41%.

Earnings Estimates

There are 3 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.38 for the current quarter, with a high estimate of -$0.19 and a low estimate of -$0.54, while EPS last year was -$0.47. The consensus estimate for the next quarter is $0.13, with high estimates of $0.23 and low estimates of -$0.03.

Analysts are recommending an EPS of between -$0.22 and -$0.77 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$1.09, with 2 analysts recommending between -$0.39 and -$1.79.

Revenue Estimates

A total of 2 analysts believe the company’s revenue will be $32.79M this quarter.It ranges from a high estimate of $33.38M to a low estimate of $32.2M. As of the current estimate, Lucira Health Inc.’s year-ago sales were $18.3M, an estimated increase of 79.20% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $90.01M, an increase of 47.30% less than the figure of $79.20% in the same quarter last year. There is a high estimate of $110.02M for the next quarter, whereas the lowest estimate is $80M.

A total of 3 analysts have provided revenue estimates for LHDX’s current fiscal year. The highest revenue estimate was $258.84M, while the lowest revenue estimate was $230M, resulting in an average revenue estimate of $239.96M. In the same quarter a year ago, actual revenue was $93.06M, up 157.90% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $207.5M in the next fiscal year. The high estimate is $220M and the low estimate is $195M. The average revenue growth estimate for next year is down -13.50% from the average revenue estimate for this year.